Cancer

Roche’s tumour-agnostic drug approved by FDA, priced under competitor drug

19-Aug-2019 By Vassia Barba

Roche receives US FDA approval with two indications for Rozlytrek, prices the drug at almost half of Bayer’s similar drug.

Onconova adopts single-cell DNA analysis platform

13-Aug-2019 By Vassia Barba

Onconova to use Mission Bio’s Tapestri targeted single-cell DNA analysis platform to advance its cancer therapy, rigosertib, into Phase III clinical trials.

Cancer Research UK backs Hummingbird’s cancer treatment development

13-Aug-2019 By Vassia Barba

Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.

AI platform identifies anti-cancer uses in non-cancer generics

08-Aug-2019 By Vassia Barba

'Oncology Repurposing Engine' uses artificial intelligence to identify potential drug candidates among generics and off-patent drugs that may be repurposed as cancer therapies.

PPD expands patient access to clinical trials via collaboration with cancer center

16-Jul-2019 By Melissa Fassbender

PPD’s patient enrollment business expands access to cancer patients treated in the community setting as part of a new collaboration with a hospital and outpatient center network.

‘Increasing visibility’: Repositive relaunches Cancer Models platform with accessible directory

11-Jul-2019 By Maggie Lynch

Repositive ‘increases visibility’ while ‘maintaining confidentiality’ as it makes its directory of preclinical cancer models publicly browsable as part of the relaunch of its Cancer Models Platform.

On the basis of genetics: Clinical trial alliance focuses recruitment on DNA

21-May-2019 By Maggie Lynch

Kazia therapeutics is collaborating with the Alliance for Clinical Trials in Oncology Foundation to launch a Phase II study to investigate its brain cancer therapies targeted at tumors’ genetic profile.

Almac expands neo-antigen peptide manufacturing

02-Jan-2019 By Maggie Lynch

Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.

Repositive expands preclinical cancer model offering

26-Nov-2018 By Maggie Lynch

Repostive expanded its cancer models offering to include cell-line derived xenograft (CDX) models, syngeneic, and humanized mouse models.

Novartis spends $2.1bn on candidate with blockbuster potential

23-Oct-2018 By Maggie Lynch

Novartis will acquire Endocyte for $2.1bn, with the core of the deal centering on the latter’s experimental therapy for prostate cancer.

Mallinckrodt inks licensing agreement for commercialization of cancer preventative drug

27-Aug-2018 By Maggie Lynch

Cancer Prevention Pharmaceuticals has signed a licensing agreement with Mallinckrodt Pharma for commercialization rights to its lead drug candidate.

Boehringer Ingelheim CDMO providing CMC services for Ph Ib/III trial of cancer antibody

22-Aug-2018 By Melissa Fassbender

Boehringer Ingelheim’s China-based CDMO is providing clinical trial materials for CANbridge Life Sciences' Phase Ib/III study of its drug candidate intended to treat esophageal cancer.

Almac and Elasmogen receive £2m grant for oncology research

13-Aug-2018 By Maggie Lynch

Almac Discovery is collaborating with Elasmogen to further oncology research after being granted £2m by Innovate UK.

Scope 2018

TriNetX releases new algorithm to aid clinical trial patient identification

21-Feb-2018 By Melissa Fassbender

The global health research network TriNetX has developed a new chemotherapy lines of treatment identification algorithm to help researchers identify potential clinical trial patients.

Alligator back for more, expands CRO collaboration with Theradex

29-Jan-2018 By Flora Southey

Alligator Bioscience says an existing agreement with Theradex informed its decision to re-sign the CRO, this time to test metastatic cancer candidate ATOR-1015.

Scientists look to regenerative 'chemo-catalyst' for more selective cancer drugs

16-Jan-2018 By Flora Southey

A natural substance found in stinging nettles and ants repeatedly attacks cancer within cells, say scientists developing low-dose alternatives to current chemotherapy drugs.

New trial design guidelines address ‘inappropriate’ patient exclusion

15-Jan-2018 By Melissa Fassbender

Exclusion of brain metastasis patients from clinical trials of anti-cancer drugs could remove up to two-thirds of the stage IV population, say researchers who have published new guidelines aimed at bringing attention to opportunities for improvement.

Charles River acquires UK-based KWS BioTest for $20m

11-Jan-2018 By Melissa Fassbender

Charles River Laboratories has acquired KWS BioTest in a deal that will expand the company’s immunology contract research services and geographical footprint.

Aslan to make Array's small molecule cancer drug varlitinib under new licensing deal

08-Jan-2018 By Gareth Macdonald

Aslan Pharmaceuticals Pte Ltd has licensed manufacturing and sales rights to Array BioPharma’s candidate small molecule pan-HER inhibitor varlitinib.

Seaweed extracts could inhibit cancer cell growth, says Australian biotech

06-Dec-2017 By Flora Southey

Seaweed extracts can reduce tumour growth and improve the effectiveness of chemotherapy says Marinova, which is developing the compounds for pharmaceutical applications.

ATCC adds novel in vitro model to expanding portfolio

23-Nov-2017 By Melissa Fassbender

ATCC has released an in vitro model system for a key mechanism of invasion and metastasis in lung cancer as the company continues its efforts to provide drug discovery and development services.

Charles River teams up with 3D cell culture tech provider to expand in vitro oncology services

01-Nov-2017 By Melissa Fassbender

Charles River is extending its preclinical services through a partnership with InSphero AG – “further affirmation” of its commitment to the in vitro oncology space, says executive director.

Anti-malaria drug casts light on cancer therapy

25-Sep-2017 By Flora Southey

A treatment combining anti-malaria drug artemisinin and light-sensitive molecules could kill cancer cells and hinder tumour growth, say researchers.

Recipharm to make clinical trial cancer candidate for Kancera

18-Sep-2017 By Dan Stanton

Recipharm will make clinical trial capsules to support oncology candidate KAND567, a former AstraZeneca Fractalkine receptor inhibitor being developed by Kancera.

Clinical trial exclusion criteria growing in complexity and number

11-Sep-2017 By Melissa Fassbender

Clinical trial exclusion criteria has increased nearly 60% over the last 30 years – and may decrease the likelihood of successful trial completion and generalizability of results, say researchers.

Recipharm installs dedicated production line for prostate cancer depot

26-Jul-2017 By Dan Stanton

Recipharm has installed a dedicated production line to make prostate cancer drug Liproca Depot for Swedish pharma firm LIDDS AB.

Q&A

Cancer in the Asia-Pacific, a CRO perspective

10-Jul-2017 By Flora Southey

As cancer rates increase in the Asia-Pacific region, and clinical trial capabilities grow in India and China, demand for research is on the rise.

Newlink expands indoximod IP with US prodrug patent

10-Jul-2017 By Gareth Macdonald

Newlink Genetics Corporation has expended its indoximod IP portfolio weeks after data suggested the cancer drug may make Provenge and Keytruda more effective.

CRO Pharmatest, Taconic create first-of-its-kind model for bone metastasis

10-Jul-2017 By Melissa Fassbender

The preclinical CRO Pharmatest has developed an animal model to clarify the role of human immune cells in bone metastases using Taconic Biosciences’ huNOG model.

Takeda inaugurates €100m German oral solid dose plant

20-Jun-2017 By Staff Reporter

Takeda has completed a €100m ($112m) oral solid dosage production facility in Germany.

Merck & Co pauses two Ph III Keytruda studies after patient deaths

14-Jun-2017 By Gareth Macdonald

Merck & Co has halted two Phase III studies examining its drug Keytruda (pembrolizumab) in combination with other therapies after reports of patient deaths.

Approval for biomarker-based Keytruda a US FDA first

01-Jun-2017 By Flora Southey

US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed.

Charles River partners with CRO to expand PDX model capabilities

22-May-2017 By Melissa Fassbender

Charles River Laboratories International, Inc. has partnered with OcellO to expand its PDX model capabilities and has made several additions to its online Tumor Model Compendium.

CRO George Clinical extends oncology research in Asia Pacific and US

03-May-2017 By Flora Southey

Asia Pacific-based CRO George Clinical has acquired Vector Oncology's CRO division in the US to expand cancer research across the regions.

PharmaCell to make autologous cell therapies for Lion Biotech

28-Apr-2017 By Flora Southey

Dutch contract manufacturer PharmaCell B.V has signed a three-year Manufacturing Services Agreement to make cancer cell therapies for Lion Biotechnologies.

Caligor supporting Puma's expanded access program for breast cancer therapy

20-Apr-2017 By Melissa Fassbender

Caligor Opco LLC is providing regulatory and logistical management for Puma Biotechnology’s expanded access program (EAP) for its investigational breast cancer therapy, neratinib.

Envigo announces new double knockout mouse model

04-Apr-2017 By Melissa Fassbender

Envigo has launched a mixed-background mouse to support oncology, immuno-oncology, and infectious disease research.

CRO-less trial of malaria generic uses crowdfunding to treat bowel cancer

08-Mar-2017 By Dani Bancroft

In the absence of a CRO, the 200 patient NeoART study is relying on the UK NHS, crowdfunding and charity to trial an antimalarial generic for late stage bowel cancer.

Almac selected as preferred partner for EORTC clinical trials

08-Mar-2017 By Melissa Fassbender

Almac Diagnostics will initiate sample profiling on current EORTC trials to further biomarker discovery and development.

New CRO Helomics partners up on prostate cancer liquid biopsies

16-Jan-2017 By Dani Bancroft

Helomics has signed a deal with the diagnostics firm MDNA Life Sciences Inc., to help further develop MDNA’s liquid biopsy platform and commercialize its tests for prostate cancer.

COLD CHAIN

Cryoport to deliver Gradalis autologus immuno-oncology therapies across US

05-Jan-2017 By Dani Bancroft

Cryoport’s network of cold chain logistics will support the delivery of Gradalis Inc’s autologous cell therapy to various cancer trial sites across the US.

Preclinical imaging system aids translational research

02-Nov-2016 By Melissa Fassbender

The NORLUX Neuro-Oncology Laboratory has installed MR Solutions’ preclinical scanner to advance cancer research and translation to clinical applications.

Flexible molecules could be better drugs - for some targets

31-Aug-2016 By Phil Taylor

For drug molecules, having a flexible rather than a rigid structure can sometimes make you a better medicine, say scientists in California.

Ziopharm investigating death in Ph I trial of brain cancer gene therapy

18-Jul-2016 By Gareth Macdonald

Ziopharm Oncology has started investigating a death that occured during a Ph I trial of its candidate brain cancer gene therapy, Ad-RTS-hIL-12.

NCI: global initiative to create 1,000 cancer cell models

18-Jul-2016 By Melissa Fassbender

A newly-launched international project seeks to develop a new bank of cancer cell culture models for the research community.

CrownBio introduces new recombinant cell lines for oncology drug discovery

11-Jul-2016 By Melissa Fassbender

CrownBio’s new stable cell lines feature various immune checkpoints and receptors which are key targets and pathways for oncology drug discovery and development.